Trials / Completed
CompletedNCT06352892
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
A Phase 1, Open-label, Randomized, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 133 Administered Subcutaneously in Chinese Subjects With Obesity or Overweight
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objective of the study is to assess the pharmacokinetics (PK) of Maridebart Cafraglutide after a single subcutaneous (SC) administration in overweight or obese Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maridebart Cafraglutide | Solution for SC injection. |
Timeline
- Start date
- 2024-04-25
- Primary completion
- 2024-08-27
- Completion
- 2024-08-27
- First posted
- 2024-04-08
- Last updated
- 2026-01-08
Locations
1 site across 1 country: Hong Kong
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06352892. Inclusion in this directory is not an endorsement.